Misplaced Pages

Travoprost/timolol, sold under the brand name Duotrav among others, is a fixed-dose combination medication used for the treatment of glaucoma. It contains travoprost and timolol maleate.

It was approved for medical use in the European Union in April 2006.

References

1. ^ "Travoprost/timolol Product Information" (PDF). TGA eBS. Retrieved 23 May 2021.
2. "DUOTRAV travoprost 0.004% and timolol 0.5% (as maleate) eye drop solution". Department of Health. Australian Government.
3. "DuoTrav eye drops solution - Summary of Product Characteristics (SmPC)". (emc). 14 June 2018. Retrieved 30 October 2020.
4. ^ "Duotrav EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 October 2020.
5. Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL (2012). "Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis". PLOS ONE. 7 (9): e45079. Bibcode:2012PLoSO...745079C. doi:10.1371/journal.pone.0045079. PMC 3441590. PMID 23028770.
6. Konstas AG, Quaranta L, Realini T (April 2012). "Overview of the travoprost /timolol BAK-free fixed combination". Expert Opinion on Pharmacotherapy. 13 (5): 757–66. doi:10.1517/14656566.2012.662485. PMID 22360540. S2CID 24160793.
7. Denis P (February 2011). "Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review". Expert Opinion on Pharmacotherapy. 12 (3): 463–71. doi:10.1517/14656566.2011.551007. PMID 21254951. S2CID 46258207.

External links

• "Timolol maleate mixture with Travoprost". Drug Information Portal. U.S. National Library of Medicine.

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Combination drugs
• Ophthalmology drugs
• Pharmacology stubs